Twenty-one mRNA candidates used in this study are presented in Fig 5; some were reported to be biomarkers in previous studies (e.g., DDIT4 [63], PLA2G4A [64], RAB27B [65], CD163 [66], CALCRL [67], SLC8A1 [68], CRISPLD1 [69], PDE7B [70], PRDM16 [71], and KIAA0087 [72]), and some were reported to be novel target mRNAs or to require further validation for their role in AML (e.g., SCHIP1, LGALSL, SORT1, HTR1F, CLIP4, RTN1, KCNJ2, CPNE8, STOX2, GLIS3, and ADAMTS3). This evidence concerns the gene PRDM16 and acute myeloid leukemia.